Extended difficulties following the use of psychedelic drugs: A mixed methods study
Jules Evans, Oliver Robinson, Eirini K. Argyri, Shayam Suseelan, Ashleigh Murphy-Beiner, Rosalind McAlpine, David Luke, Katrina Michelle, Ed Prideaux
PLoS One October 24, 2023 DOI: 10.1371/journal.pone.0293349 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Convergent mixed-method study Qualitative Peer reviewed |
|---|---|
| Sample size | 608 |
| Population | Participants who reported extended difficulties following psychedelic experiences |
| Topics | Anxiety Psilocybin |
| Keywords | Context archaeology Feeling Depersonalization Disconnection Clinical psychology Harm reduction Hallucinogen Public health |
| Citations | 166 |
| Key points | The most common extended difficulties were anxiety and fear, existential struggle, social disconnection, depersonalization, and derealization, with about one-third of participants experiencing problems for over a year. |
Abstract
Long-term adverse experiences following psychedelic use can persist for weeks, months, or even years, and are relatively unexplored in psychedelic research. Our convergent mixed-method study gained quantitative and qualitative data from 608 participants who reported extended difficulties following psychedelic experiences. Data was gathered on the context of use, the nature and duration of the challenges they experienced (including a written description of these), plus a range of possible risk factors and perceived causes. The most common forms of extended difficulty were feelings of anxiety and fear, existential struggle, social disconnection, depersonalization and derealization. For approximately one-third of the participants, problems persisted for over a year, and for a sixth, they endured for more than three years. It was found that a shorter duration of difficulties was predicted by knowledge of dose, drug type and lower levels of difficulty reported during the psychoactive experience, while a narrower range of difficulties was predicted by taking the drug in a guided setting. Implications for psychedelic harm reduction are discussed.